文献速递脊柱关节炎

乌帕替尼在早期与established axSpA亚组患者中的疗效比较

Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease.
PubMed 文献 · RMD Open · 2025-03-04

基于SELECT-AXIS 1和2研究,评估乌帕替尼在bDMARD初治或应答不佳的axSpA患者中按症状 duration 分层的疗效。第14周时,无论症状 duration 长短,乌帕替尼在所有终点均优于安慰剂;除nr-axSpA组早期疾病的高敏C反应蛋白变化更优外,早期与established亚组间无统计学显著差异。

要点

  • 第14周时,乌帕替尼在所有评估终点均优于安慰剂,不受症状 duration 影响。
  • 早期与established亚组间所有指标均无统计学显著差异,仅nr-axSpA组高敏C反应蛋白变化早期更优。
  • nr-axSpA组高敏C反应蛋白自基线变化差异为-8.2(95%CI -14.9至-1.6),早期疾病应答更佳。

核心结论

  • 就短期结局而言,症状 duration 较短(≤2年)与较长(>2年)的axSpA患者接受乌帕替尼治疗可获得可比的结果。

研究设计与样本

  • SELECT-AXIS 1和2研究纳入对bDMARD初治及对bDMARD不耐受或应答不佳的r-axSpA和nr-axSpA患者。
  • 按症状 duration 分层:nr-axSpA分为早期与established(≤2年 vs >2年,采用ASAS定义)及较短与较长(≤5年 vs >5年);r-axSpA分为≤5年 vs >5年。
  • 疗效终点评估至第14周,包括ASDAS和ASAS40应答率等。
  • 通过相对危险度(RR)评估乌帕替尼 vs 安慰剂在所有终点的疗效,通过RR比值评估较短 vs 较长症状 duration 间乌帕替尼的安慰剂校正效应。

主要发现

  • 第14周时,无论症状 duration 长短,乌帕替尼治疗患者在 all 评估终点均观察到优于安慰剂的应答。
  • 比较早期/较短与established/较长症状 duration 患者,所有评估指标均未观察到统计学显著差异,唯nr-axSpA组高敏C反应蛋白自基线变化例外,早期疾病应答更优(差异-8.2,95%CI -14.9至-1.6)。

关键数值与推荐

  • nr-axSpA组高敏C反应蛋白自基线变化:早期疾病更优,差异-8.2(95%CI -14.9至-1.6)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Early disease activity control with targeted therapies may improve long-term outcomes in axial spondyloarthritis (axSpA). Here, we evaluated the efficacy of upadacitinib in patients with axSpA with shorter versus longer symptom durations. METHODS: SELECT-AXIS 1 and 2 studies enrolled patients with radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) naïve to biologic disease-modifying antirheumatic drugs (bDMARD-naïve) and with an intolerance or inadequate response to bDMARD therapy. Patients were stratified by symptom duration (nr-axSpA: early vs established (≤2 vs >2 years=Assessment of SpondyloArthritis international Society (ASAS) definition) and shorter vs longer (≤5 vs >5 years); r-axSpA: ≤5 vs >5 years). Efficacy endpoints assessed through week 14 included the proportion of patients achieving Axial Spondyloarthritis Disease Activity Score and ASAS40 responses, among others. Across all endpoints, the efficacy of upadacitinib versus placebo was assessed by relative risk (RR), and the placebo-adjusted effect of upadacitinib between shorter versus longer symptom duration was assessed by the RR ratio. RESULTS: At week 14, better responses were observed in patients treated with upadacitinib in all endpoints assessed compared with placebo, regardless of symptom duration. When comparing patients with early/shorter versus established/longer symptom durations, for all measures assessed, no statistically significant differences were observed except for the change from baseline in high-sensitivity C-reactive protein in the nr-axSpA group, with a better response in early disease (difference -8.2, 95% CI -14.9 to -1.6). CONCLUSION: Regarding short-term outcomes, both subgroups of patients (shorter axSpA symptom duration (≤2 years) and longer symptom duration (>2 years)) achieved comparable results when treated with upadacitinib. TRIAL REGISTRATION NUMBER: NCT03178487 (SELECT-AXIS 1) and NCT04169373 (SELECT-AXIS 2).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Navarro-Compán V, Van den Bosch F, Sampaio-Barros PD, et al. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025. PMID: 40037923. doi:10.1136/rmdopen-2024-005110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。